Cargando…

Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin

Adriamycin, a widely used anthracycline antibiotic in multiple chemotherapy regimens, has been challenged by the cardiotoxicity leading to fatal congestive heart failure in the worst condition. The present study demonstrated that Dihydromyricetin, a natural product extracted from ampelopsis grossede...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hong, Luo, Peihua, Fu, Yingying, Wang, Jincheng, Dai, Jiabin, Shao, Jinjin, Yang, Xiaochun, Chang, Linlin, Weng, Qinjie, Yang, Bo, He, Qiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413651/
https://www.ncbi.nlm.nih.gov/pubmed/25226612
_version_ 1782368815556853760
author Zhu, Hong
Luo, Peihua
Fu, Yingying
Wang, Jincheng
Dai, Jiabin
Shao, Jinjin
Yang, Xiaochun
Chang, Linlin
Weng, Qinjie
Yang, Bo
He, Qiaojun
author_facet Zhu, Hong
Luo, Peihua
Fu, Yingying
Wang, Jincheng
Dai, Jiabin
Shao, Jinjin
Yang, Xiaochun
Chang, Linlin
Weng, Qinjie
Yang, Bo
He, Qiaojun
author_sort Zhu, Hong
collection PubMed
description Adriamycin, a widely used anthracycline antibiotic in multiple chemotherapy regimens, has been challenged by the cardiotoxicity leading to fatal congestive heart failure in the worst condition. The present study demonstrated that Dihydromyricetin, a natural product extracted from ampelopsis grossedentat, exerted cardioprotective effect against the injury in Adriamycin-administrated ICR mice. Dihydromyricetin decreased ALT, LDH and CKMB levels in mice serum, causing a significant reduction in the toxic death triggered by Adriamycin. The protective effects were also indicated by the alleviation of abnormal electrocardiographic changes, the abrogation of proliferation arrest and apoptotic cell death in primary myocardial cells. Further study revealed that Dihydromyricetin-rescued loss of anti-apoptosis protein ARC provoked by Adriamycin was involved in the cardioprotection. Intriguingly, the anticancer activity of Adriamycin was not compromised upon the combination with Dihydromyricetin, as demonstrated by the enhanced anticancer effect achieved by Adriamycin plus Dihydromyricetin in human leukemia U937 cells and xenograft models, in a p53-dependent manner. These results collectively promised the potential value of Dihydromyricetin as a rational cardioprotective agent of Adriamycin, by protecting myocardial cells from apoptosis, while potentiating anticancer activities of Adriamycin, thus further increasing the therapeutic window of the latter one.
format Online
Article
Text
id pubmed-4413651
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-44136512015-05-08 Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin Zhu, Hong Luo, Peihua Fu, Yingying Wang, Jincheng Dai, Jiabin Shao, Jinjin Yang, Xiaochun Chang, Linlin Weng, Qinjie Yang, Bo He, Qiaojun Oncotarget Research Paper Adriamycin, a widely used anthracycline antibiotic in multiple chemotherapy regimens, has been challenged by the cardiotoxicity leading to fatal congestive heart failure in the worst condition. The present study demonstrated that Dihydromyricetin, a natural product extracted from ampelopsis grossedentat, exerted cardioprotective effect against the injury in Adriamycin-administrated ICR mice. Dihydromyricetin decreased ALT, LDH and CKMB levels in mice serum, causing a significant reduction in the toxic death triggered by Adriamycin. The protective effects were also indicated by the alleviation of abnormal electrocardiographic changes, the abrogation of proliferation arrest and apoptotic cell death in primary myocardial cells. Further study revealed that Dihydromyricetin-rescued loss of anti-apoptosis protein ARC provoked by Adriamycin was involved in the cardioprotection. Intriguingly, the anticancer activity of Adriamycin was not compromised upon the combination with Dihydromyricetin, as demonstrated by the enhanced anticancer effect achieved by Adriamycin plus Dihydromyricetin in human leukemia U937 cells and xenograft models, in a p53-dependent manner. These results collectively promised the potential value of Dihydromyricetin as a rational cardioprotective agent of Adriamycin, by protecting myocardial cells from apoptosis, while potentiating anticancer activities of Adriamycin, thus further increasing the therapeutic window of the latter one. Impact Journals LLC 2014-09-05 /pmc/articles/PMC4413651/ /pubmed/25226612 Text en Copyright: © 2015 Zhu et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zhu, Hong
Luo, Peihua
Fu, Yingying
Wang, Jincheng
Dai, Jiabin
Shao, Jinjin
Yang, Xiaochun
Chang, Linlin
Weng, Qinjie
Yang, Bo
He, Qiaojun
Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin
title Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin
title_full Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin
title_fullStr Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin
title_full_unstemmed Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin
title_short Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin
title_sort dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413651/
https://www.ncbi.nlm.nih.gov/pubmed/25226612
work_keys_str_mv AT zhuhong dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin
AT luopeihua dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin
AT fuyingying dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin
AT wangjincheng dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin
AT daijiabin dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin
AT shaojinjin dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin
AT yangxiaochun dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin
AT changlinlin dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin
AT wengqinjie dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin
AT yangbo dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin
AT heqiaojun dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin